Zhaoke Ophthalmology Anticipates Approval for Eye Medications in China This Year

Zhaoke Ophthalmology is currently seeking approval from China's National Medical Products Administration for the commercialization of three ophthalmic medications. According to Ming Pao, Chairman and Executive Director Li Xiaoyi expressed optimism about receiving approval within this year, paving the way for commercialization. Prior to this, Li anticipates a significant increase in marketing and promotional expenses, along with personnel allocation. Li also disclosed plans to expand into overseas markets, with expectations to generate revenue starting in 2028 following overseas registration and approval. The company aims for international sales to eventually constitute half of its total revenue, with a strategic focus on entering the Latin American market, particularly Brazil. Additionally, Zhaoke Ophthalmology has initiated registration processes for its products in Hong Kong and Macau, aiming for broader application within the Greater Bay Area.